臨床神経学および脳神経外科ジャーナル

Deep Brain Stimulation (DBS) has emerged as a transformative intervention for managing movement disorders, including Parkinson's Disease (PD), Essential Tremor (ET) and Dystonia. This meta-analysis aims to synthesize long-term outcomes of DBS therapy, focusing on efficacy, safety and quality of life. By evaluating data from multiple studies, we provide a comprehensive overview of how DBS impacts patients with movement disorders over extended periods. Deep Brain Stimulation, a neurosurgical technique involving the implantation of electrodes into specific brain regions, has been shown to offer significant benefits to patients with various movement disorders. As DBS technology evolves and its application expands, understanding the long-term outcomes becomes crucial for optimizing patient care and guiding clinical decision-making. This metaanalysis collates data from longitudinal studies to evaluate the sustainability of DBS benefits and the incidence of long-term complications.

Drug-resistant epilepsy presents a significant challenge in neurology and neurosurgery. Despite advancements in pharmacological treatments, a substantial proportion of patients experience persistent seizures that do not respond to conventional anti-seizure medications. For these individuals, surgical intervention offers a promising alternative. Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures resulting from abnormal electrical activity in the brain. While many patients achieve satisfactory seizure control with Anti-Seizure Medications (ASMs), a substantial subset of individuals, termed Drug-Resistant Epilepsy (DRE), continues to experience seizures despite treatment. Understanding drug-resistant epilepsy involves exploring its definition, causes, diagnostic challenges and impact on patients.

Neurosurgical research, a critical field advancing our understanding of the brain and nervous system, presents unique ethical and consent challenges. Neurosurgical research often involves invasive procedures, including brain surgery, that carry significant risks. The potential benefits, such as advancements in treatments for neurological disorders, must be weighed against these risks. This balance necessitates a rigorous ethical framework to guide research practices and protect patient interests. Neurosurgical research is at the forefront of medical science, striving to unlock the mysteries of the brain and nervous system to develop innovative treatments for neurological disorders. However, the field's inherent complexity presents multifaceted challenges that researchers must navigate carefully.

Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS), present significant challenges in both diagnosis and treatment. Advances in precision medicine offer promising new avenues for personalized approaches to these complex disorders. This article explores current practices in precision medicine for neurodegenerative diseases, highlights key advancements and outlines potential future directions for research and clinical application. Neurodegenerative diseases are characterized by the progressive degeneration of the structure and function of the nervous system. These conditions are notoriously difficult to diagnose early and to treat effectively due to their complex and multifactorial nature. Traditional approaches to treatment have often been one-size-fits-all, but the emergence of precision medicine—an approach tailored to the individual characteristics of each patient—promises to transform this landscape.